The tweet was deleted by the author.
But we saved everything 🙂.
Zevra Therapeutics announced the FDA Orange Book listing of a U.S. patent that extends the company's exclusivity protection through November 2041.
This move is aimed at advancing innovation for the rare disease community and further solidifies Zevra Therapeutics' intellectual property portfolio. The company emphasized that this milestone demonstrates its ongoing commitment to developing treatments for rare diseases, ensuring long-term protection and market position for its proprietary therapies.
Zevra Therapeutics recently presented findings from its NPC002 trial and a genotype analysis for Niemann-Pick disease Type C at SIMD2026 on May 18. The company also shared business updates during a fireside chat led by CEO Neil McFarlane at the H.C. Wainwright BioConnect Investor Conference on May 19. These activities reflect the company's continued engagement with both scientific and investor communities.